BioSpace News Archive

Cipher Pharmaceuticals Inc. announced its financial and operating results for the three and nine months ended September 30, 2019. Unless otherwise noted, all figures are in U.S. dollars..

Bio-Techne Corporation announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 1:50 p.m. EST.

Anixa Biosciences, Inc., a biotechnology company focused on harnessing the body’s immune system in the fight against cancer, announced that data from its ongoing studies utilizing Cchek™, its artificial intelligence driven early cancer detection technology will be displayed in a poster presentation at the Cell Symposia: Hallmarks of Cancer.

Affron® eco-friendly technology maximizes “liquid gold” concentration and potency

EIP Pharma, Inc., a CNS-focused therapeutics company, announced that the REVERSE-SD study of neflamapimod in early-stage Alzheimer’s disease met its secondary objectives of target engagement and proof-of-mechanism demonstrating statistically significant reductions relative to placebo in cerebrospinal fluid levels of phospho-tau and tau, the major markers of neurodegeneration and axonal damage.

Phase 2 clinical trial of neflamapimod in patients with mild-to-moderate DLB currently enrolling patients in the U.S. and the Netherlands

CASI Pharmaceuticals, Inc., a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announces an exclusive distribution agreement with Pharmathen Global BV for the development and distribution of octreotide long acting injectable microsphere in China.

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, reported financial results for the third quarter ended September 30, 2019, and provided a business update.

Concert Pharmaceuticals, Inc. reported financial results for the third quarter of 2019.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, announced that management will present at two upcoming investor conferences